586 related articles for article (PubMed ID: 28276774)
1. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
Cernea S; Cahn A; Raz I
Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
3. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
4. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Budd J; Cusi K
Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
[TBL] [Abstract][Full Text] [Related]
5. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
6. Promising therapies for treatment of nonalcoholic steatohepatitis.
Noureddin M; Zhang A; Loomba R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological management of nonalcoholic fatty liver disease.
Barb D; Portillo-Sanchez P; Cusi K
Metabolism; 2016 Aug; 65(8):1183-95. PubMed ID: 27301803
[TBL] [Abstract][Full Text] [Related]
8. [Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].
Чопей ІВ; Івачевська ВВ; Чубірко КІ; Гряділь ТІ; Гечко ММ
Wiad Lek; 2017; 70(2):169-173. PubMed ID: 28511152
[TBL] [Abstract][Full Text] [Related]
9. Steatosis and NASH in type 2 diabetes.
Hu M; Phan F; Bourron O; Ferré P; Foufelle F
Biochimie; 2017 Dec; 143():37-41. PubMed ID: 29097281
[TBL] [Abstract][Full Text] [Related]
10. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Blazina I; Selph S
Syst Rev; 2019 Nov; 8(1):295. PubMed ID: 31783920
[TBL] [Abstract][Full Text] [Related]
11. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
Bril F; Kalavalapalli S; Clark VC; Lomonaco R; Soldevila-Pico C; Liu IC; Orsak B; Tio F; Cusi K
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):558-566.e2. PubMed ID: 29223443
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.
Bril F; Cusi K
Endocrinol Metab Clin North Am; 2016 Dec; 45(4):765-781. PubMed ID: 27823604
[TBL] [Abstract][Full Text] [Related]
13. [Non-alcoholic fatty liver disease and type 2 diabetes mellitus. II. Treatment].
Pár A; Wittmann I; Pár G
Orv Hetil; 2022 May; 163(22):855-862. PubMed ID: 35895614
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
15. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Corey KE; Rinella ME
Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
[TBL] [Abstract][Full Text] [Related]
16. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
Lonardo A; Lugari S; Ballestri S; Nascimbeni F; Baldelli E; Maurantonio M
Acta Diabetol; 2019 Apr; 56(4):385-396. PubMed ID: 30519965
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
Kuchay MS; Choudhary NS; Mishra SK; Misra A
Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
[TBL] [Abstract][Full Text] [Related]
18. Multi-drug approaches to NASH: what's in the development pipeline?
Johnston MP; Patel J; Byrne CD
Expert Opin Investig Drugs; 2020 Feb; 29(2):143-150. PubMed ID: 31524533
[No Abstract] [Full Text] [Related]
19. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.
Pafili K; Roden M
Mol Metab; 2021 Aug; 50():101122. PubMed ID: 33220492
[TBL] [Abstract][Full Text] [Related]
20. Approach to the Patient With Nonalcoholic Fatty Liver Disease.
Belfort-DeAguiar R; Lomonaco R; Cusi K
J Clin Endocrinol Metab; 2023 Jan; 108(2):483-495. PubMed ID: 36305273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
